175 related articles for article (PubMed ID: 32912923)
1. BRAF inhibitor resistance of melanoma cells triggers increased susceptibility to natural killer cell-mediated lysis.
Frazao A; Rethacker L; Jeudy G; Colombo M; Pasmant E; Avril MF; Toubert A; Moins-Teisserenc H; Roelens M; Dalac S; Maubec E; Caignard A
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32912923
[TBL] [Abstract][Full Text] [Related]
2. Clearing soluble MIC reverses the impaired function of natural killer cells from patients with multiple myeloma.
Kim S; Chung H; Kwak JE; Kim YR; Park CH; Kim Y; Cheong JW; Wu J; Shin EC; Cho H; Kim JS
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38191242
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of tumor cell susceptibility to natural killer cell activity through inhibition of the PI3K signaling pathway.
Bommarito D; Martin A; Forcade E; Nastke MD; Ritz J; Bellucci R
Cancer Immunol Immunother; 2016 Mar; 65(3):355-66. PubMed ID: 26883876
[TBL] [Abstract][Full Text] [Related]
4. Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines.
Casado JG; Pawelec G; Morgado S; Sanchez-Correa B; Delgado E; Gayoso I; Duran E; Solana R; Tarazona R
Cancer Immunol Immunother; 2009 Sep; 58(9):1517-26. PubMed ID: 19259667
[TBL] [Abstract][Full Text] [Related]
5. Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma.
Hooijkaas A; Gadiot J; Morrow M; Stewart R; Schumacher T; Blank CU
Oncoimmunology; 2012 Aug; 1(5):609-617. PubMed ID: 22934253
[TBL] [Abstract][Full Text] [Related]
6. Treatment combinations targeting apoptosis to improve immunotherapy of melanoma.
Hersey P; Zhang XD
Cancer Immunol Immunother; 2009 Nov; 58(11):1749-59. PubMed ID: 19551381
[TBL] [Abstract][Full Text] [Related]
7. Ccr2+ Monocyte-Derived Macrophages Influence Trajectories of Acquired Therapy Resistance in Braf-Mutant Melanoma.
Kim D; An L; Moon J; Maymi VI; McGurk AI; Rudd BD; Fowell DJ; White AC
Cancer Res; 2023 Jul; 83(14):2328-2344. PubMed ID: 37195124
[TBL] [Abstract][Full Text] [Related]
8. Osteoblasts contribute to a protective niche that supports melanoma cell proliferation and survival.
Ferguson J; Wilcock DJ; McEntegart S; Badrock AP; Levesque M; Dummer R; Wellbrock C; Smith MP
Pigment Cell Melanoma Res; 2020 Jan; 33(1):74-85. PubMed ID: 31323160
[TBL] [Abstract][Full Text] [Related]
9. ALDH1A1 confers resistance to RAF/MEK inhibitors in melanoma cells by maintaining stemness phenotype and activating PI3K/AKT signaling.
Ciccone V; Simonis V; Del Gaudio C; Cucini C; Ziche M; Morbidelli L; Donnini S
Biochem Pharmacol; 2024 Jun; 224():116252. PubMed ID: 38701866
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of Acquired BRAF Inhibitor Resistance in Melanoma: A Systematic Review.
Proietti I; Skroza N; Bernardini N; Tolino E; Balduzzi V; Marchesiello A; Michelini S; Volpe S; Mambrin A; Mangino G; Romeo G; Maddalena P; Rees C; Potenza C
Cancers (Basel); 2020 Sep; 12(10):. PubMed ID: 33003483
[TBL] [Abstract][Full Text] [Related]
11. ERK mediates interferon gamma-induced melanoma cell death.
Champhekar A; Heymans R; Saco J; Turon Font G; Gonzalez C; Gao A; Pham J; Lee J; Maryoung R; Medina E; Campbell KM; Karin D; Austin D; Damioseaux R; Ribas A
Mol Cancer; 2023 Oct; 22(1):165. PubMed ID: 37803324
[TBL] [Abstract][Full Text] [Related]
12. The immunoglobulin superfamily ligand B7H6 subjects T cell responses to NK cell surveillance.
Kilian M; Friedrich MJ; Lu KH; Vonhören D; Jansky S; Michel J; Keib A; Stange S; Hackert N; Kehl N; Hahn M; Habel A; Jung S; Jähne K; Sahm F; Betge J; Cerwenka A; Westermann F; Dreger P; Raab MS; Meindl-Beinker NM; Ebert M; Bunse L; Müller-Tidow C; Schmitt M; Platten M
Sci Immunol; 2024 May; 9(95):eadj7970. PubMed ID: 38701193
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib promotes the TRAIL-mediated killing of resistant rhabdomyosarcoma by ErbB2/Her2-targeted CAR-NK-92 cells via DR5 upregulation.
Heim C; Hartig L; Weinelt N; Moser LM; Salzmann-Manrique E; Merker M; Wels WS; Tonn T; Bader P; Klusmann JH; van Wijk SJL; Rettinger E
Mol Ther Oncol; 2024 Jun; 32(2):200802. PubMed ID: 38706988
[TBL] [Abstract][Full Text] [Related]
14. Natural killer group 2D-major histocompatibility complex class I polypeptide-related sequence A activation enhances natural killer cell-mediated immunity against hepatocellular carcinoma: A review.
Arai J; Okumura A; Kato N; Ito K
Hepatol Res; 2024 May; 54(5):420-428. PubMed ID: 38536662
[TBL] [Abstract][Full Text] [Related]
15. SIRT2 promotes murine melanoma progression through natural killer cell inhibition.
Zhang M; Acklin S; Gillenwater J; Du W; Patra M; Yu H; Xu B; Yu J; Xia F
Sci Rep; 2021 Jun; 11(1):12988. PubMed ID: 34155309
[TBL] [Abstract][Full Text] [Related]
16. Investigational Approaches for Treatment of Melanoma Patients Progressing After Standard of Care.
Fletcher KA; Johnson DB
Cancer J; 2024 Mar-Apr 01; 30(2):126-131. PubMed ID: 38527267
[TBL] [Abstract][Full Text] [Related]
17. Low Vitamin D Status Predicts Poor Clinical Outcome in Advanced Melanoma Treated With Immune Checkpoint or BRAF/MEK Inhibitors: A Prospective Non-Interventional Side-by-Side Analysis.
Reichrath J; Biersack F; Wagenpfeil S; Schöpe J; Pföhler C; Saternus R; Vogt T
Front Oncol; 2022; 12():839816. PubMed ID: 35669434
[TBL] [Abstract][Full Text] [Related]
18. HCMV-secreted glycoprotein gpUL4 inhibits TRAIL-mediated apoptosis and NK cell activation.
Vlachava VM; Seirafian S; Fielding CA; Kollnberger S; Aicheler RJ; Hughes J; Baker A; Weekes MP; Forbes S; Wilkinson GWG; Wang ECY; Stanton RJ
Proc Natl Acad Sci U S A; 2023 Dec; 120(49):e2309077120. PubMed ID: 38011551
[TBL] [Abstract][Full Text] [Related]
19. Combinatorial Therapies to Overcome BRAF/MEK Inhibitors Resistance in Melanoma Cells: An in vitro Study.
Pópulo H; Domingues B; Sampaio C; Lopes JM; Soares P
J Exp Pharmacol; 2021; 13():521-535. PubMed ID: 34079392
[TBL] [Abstract][Full Text] [Related]
20. Retinoic acid elicits cytostatic, cytotoxic and immunomodulatory effects on uveal melanoma cells.
Vertuani S; Dubrovska E; Levitsky V; Jager MJ; Kiessling R; Levitskaya J
Cancer Immunol Immunother; 2007 Feb; 56(2):193-204. PubMed ID: 16752155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
